Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

ConditionsChronic Lymphocytic Leukemia Hematopoietic and Lymphoid System Neoplasm Mantle Cell Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorMayo Clinic

About this trial

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

Eligibility criteria

Qualifiers

Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up

Disqualifiers

Patients with known central nervous system (CNS) involvement of their B-cell malignancy

Trial design

Treatments tested in this trial

Non-Interventional Study

Treatment groups

100 Participants

are divided into 1 treatment group

Locations

Mayo Clinic in Rochester55905, RochesterMinnesota, United States

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov